{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05717920",
            "orgStudyIdInfo": {
                "id": "ADX-629-ATD-001"
            },
            "organization": {
                "fullName": "Aldeyra Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)",
            "officialTitle": "The ADRO Trial: An Adaptive, 2-Part, Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Adults With Atopic Dermatitis",
            "therapeuticArea": [
                "Dermatology"
            ],
            "study": "a-clinical-trial-in-subjects-with-atopic-dermatitis-part"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-02-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-25",
            "studyFirstSubmitQcDate": "2023-02-06",
            "studyFirstPostDateStruct": {
                "date": "2023-02-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Aldeyra Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.",
            "detailedDescription": "The trial is divided into 2 parts; the first part of the trial (Part 1) is open label, and the second part (Part 2) is randomized, double-blind, and placebo controlled.\n\nIn Part 1, approximately 10 subjects will receive open-label ADX-629 twice daily for 90 days.\n\nIn Part 2, approximately 40 subjects will be randomized to receive either ADX-629 or matching placebo twice daily for 90 days.\n\nPatients who are interested in participating will be provided detailed information about the study including description of study assessments/procedures, possible side-effects, alternative treatments, and potential benefits."
        },
        "conditionsModule": {
            "conditions": [
                "Atopic Dermatitis"
            ],
            "keywords": [
                "eczema",
                "atopic",
                "adaptive",
                "Aldeyra",
                "ADX-629",
                "Reactive aldehyde species (RASP)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "Part 1 is an open-label trial."
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ADX-629",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Part 1 ADX-629 (Open-label)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Part 1 ADX-629 (Open-label)",
                    "description": "ADX-629 (250 mg) administered BID for 90 days",
                    "armGroupLabels": [
                        "ADX-629"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Event (AE) Query",
                    "description": "Incidence and severity of AEs",
                    "timeFrame": "From Day 1 to Day 90"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Investigator Global Assessment (IGA) Score",
                    "description": "Change from Baseline in IGA Score",
                    "timeFrame": "From Day 1 to Day 90"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults \u226518 years of age\n* History of atopic dermatitis, according to American Academy of Dermatology criteria, that has been present for at least 6 months\n* Mild, moderate, or severe atopic dermatitis, defined as an IGA score of \u22652 at Baseline\n* Not pregnant, breastfeeding, or lactating and agree to use a highly effective method of acceptable contraceptive for the trial duration, if applicable\n\nExclusion Criteria:\n\n* Presence of clinically significant kidney disease or an estimated gloverular filtration rate (eGFR) of less than or equal to 45 milliliters/min/1.73 m2 during screening\n* History of any unstable chronic diseases/conditions, clinically significant abnormalities, or findings, that in the opinion of the Investigator, could compromise subject safety or affect the conduct of the trial",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Bill Cavanagh",
                    "role": "CONTACT",
                    "phone": "781-761-4904",
                    "email": "bcavanagh@aldeyra.com"
                }
            ],
            "locations": [
                {
                    "facility": "Bexley Dermatology Research",
                    "status": "RECRUITING",
                    "city": "Bexley",
                    "state": "Ohio",
                    "zip": "43209",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Matthew Zirwas, MD",
                            "role": "CONTACT",
                            "phone": "614-947-1716",
                            "email": "ablankenbuhler@docsdermgroup.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.96895,
                        "lon": -82.93768
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003876",
                    "term": "Dermatitis, Atopic"
                },
                {
                    "id": "D000003872",
                    "term": "Dermatitis"
                },
                {
                    "id": "D000004485",
                    "term": "Eczema"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000012873",
                    "term": "Skin Diseases, Genetic"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000017443",
                    "term": "Skin Diseases, Eczematous"
                },
                {
                    "id": "D000006969",
                    "term": "Hypersensitivity, Immediate"
                },
                {
                    "id": "D000006967",
                    "term": "Hypersensitivity"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7071",
                    "name": "Dermatitis, Atopic",
                    "asFound": "Atopic Dermatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7067",
                    "name": "Dermatitis",
                    "asFound": "Dermatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7655",
                    "name": "Eczema",
                    "asFound": "Atopic Dermatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15676",
                    "name": "Skin Diseases, Genetic",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M19712",
                    "name": "Skin Diseases, Eczematous",
                    "relevance": "LOW"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M10020",
                    "name": "Hypersensitivity, Immediate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}